Table 5.
Comparison of metastatic sites of uveal melanoma among various studies
| Study | Rajpal20 | COMS5 | Kath38 | Rietschel17 | Jochems39 | Mean | Our study |
| Metastasis | F/U | F/U | F/U | F/U | F/U | F/U | Presentation |
| Sample size | 35 | 739 | 24 | 119 | 175 | 218.4 | 69 |
| Liver | 71.4% | 89.0% | 87.0% | 60.5% | 88.0% | 79.2% | 91.3% |
| Lungs | 40.0% | 29.0% | 46.0% | 24.4% | 25.1% | 32.9% | 15.9% |
| Lymph nodes | 14.3% | 11.0% | 4.2% | 1.7% | 16.0% | 9.4% | 13.0% |
| Bones | 17.1% | 17.0% | 29.0% | 8.4% | 15.4% | 17.4% | 8.7% |
| Brain | 5.7% | 6.1% | 8.0% | 4.2% | 1.7% | 5.1% | 5.8% |
| Subcutaneous tissue | 34.3% | 12.0% | 17.0% | 10.9% | 10.3% | 16.9% | 4.3% |
| Others | 34.3% | 11.0% | 37.5% | N/A | 23.4% | 26.6% | 4.2% |
| Multiple sites | N/A | 43.0% | 54.2% | 10.9% | 5.7% | 28.4% | 23.2% |
| Tests | N/A | LFTs, CXR and autopsy studies | LFTs, CXR, abdominal USG, CT, MRI and autopsy studies | Radiographic imaging, blood test | Lactose dehydrogenase enzyme (LDH), Radiographic imaging | N/A | Abdominal USG, CT, MRI, and whole-body- PET or PET/CT |
| Median survival time in months (time of metastasis to death) | 2.2* | <6 | 13.2 | 12.5 | One-year survival- 47.8% | -† | 12 |
*For Rajpal20 median survival time of liver metastasis was mentioned as there was no mention of cumulative survival time and hepatic metastasis was most common.
†Mean was not calculated for median survival time.
CXR, chest X-ray; F/U, at follow-up; LFTS, liver function tests; PET, positron emission tomography; PET/CT, combination PET and CT analysis; USG, ultrasonography.